Literature DB >> 27211343

Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.

J H Volders1, M H Haloua2, N M A Krekel3, V L Negenborn2, E Barbé4, C Sietses5, K Jóźwiak6, S Meijer2, M P van den Tol2.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NACT) is increasingly used in patients with operable disease due to the potential of converting patients requiring mastectomy to breast conserving surgery (BCS) or lowering resection volumes to improve cosmetic outcome. This nationwide retrospective study aims to determine margin status and specimen volume in patients with invasive breast cancer who underwent BCS after NACT.
METHODS: All patients who underwent BCS in 2012-2013 for invasive breast cancer were selected from a nationwide network and registry of histology and cytopathology in the Netherlands (PALGA).
RESULTS: Of the 9901 patients, 626 (6.3%) received NACT. After primary surgery 949 (10.2%) patients had tumour-involved margins compared to 152 (24.3%) after NACT. Close margins (≤1 mm) were seen in another 111 (17.7%) patients after NACT. The adjusted odds ratio for involved margins after NACT was 2.94, meaning a three times higher risk of involved margins compared with primary surgery. In patients with lobular carcinoma (54.9%) and no response to NACT (42.1%) higher tumour-involved margins were seen. High resection volumes >60 cc were observed in 224 (36%) patients after NACT of which 37 (16.5%) had tumour involved margins and 32 (14.3%) close margins ≤1 mm.
CONCLUSION: The primary goal of the surgeon performing BCS after NACT, to reach tumour-free margins, is not accomplished in one out of four patients. Patients especially at risk are patients with ILC and no pathological tumour response. Excessive resection volumes after NACT do not guarantee tumour-free margins. Further research is necessary to analyze whether we are counterproductive when NACT is given in order to lower resection volumes.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Breast cancer; Breast conserving therapy; Margins; Neoadjuvant chemotherapy; Volume

Mesh:

Year:  2016        PMID: 27211343     DOI: 10.1016/j.ejso.2016.02.252

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  17 in total

1.  The Value of Repeated Breast Surgery as a Quality Indicator in Breast Cancer Care.

Authors:  Francesca Tamburelli; Riccardo Ponzone
Journal:  Ann Surg Oncol       Date:  2020-06-10       Impact factor: 5.344

Review 2.  Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Authors:  Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández
Journal:  Breast Care (Basel)       Date:  2018-07-25       Impact factor: 2.860

3.  Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy.

Authors:  Jong-Ho Cheun; Young Joo Lee; Jun-Hee Lee; Yungil Shin; Jung Whan Chun; Soo Yeon Baek; Hong-Kyu Kim; Han-Byoel Lee; Jonghan Yu; Byung Joo Chae; Wonshik Han; Jeong Eon Lee
Journal:  Breast Cancer Res Treat       Date:  2022-06-28       Impact factor: 4.624

Review 4.  Does Tumor Marking Before Neoadjuvant Chemotherapy Helps Achieve Better Outcomes in Patients Undergoing Breast Conservative Surgery? A Systematic Review.

Authors:  Chandan Kumar Jha; Goonj Johri; Prashant Kumar Singh; Sanjay Kumar Yadav; Upasna Sinha
Journal:  Indian J Surg Oncol       Date:  2021-08-03

Review 5.  Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.

Authors:  Kowsi Murugappan; Apoorva Saboo; Lu Kuo; Owen Ung
Journal:  Gland Surg       Date:  2018-12

6.  Letter to the Editor: The Impact of Neoadjuvant Chemotherapy on Margin Re-excision in Breast-Conserving Surgery.

Authors:  Dileep Ramesh Hoysal; Gaurav Agarwal
Journal:  World J Surg       Date:  2021-02-26       Impact factor: 3.352

7.  Margin Assessment and Re-excision Rates for Patients Who Have Neoadjuvant Chemotherapy and Breast-Conserving Surgery.

Authors:  Cindy Cen; Jennifer Chun; Elianna Kaplowitz; Deborah Axelrod; Richard Shapiro; Amber Guth; Freya Schnabel
Journal:  Ann Surg Oncol       Date:  2021-02-26       Impact factor: 5.344

8.  Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System.

Authors:  Suniza Jamaris; Leyla Akpolat-Basci; Miltiades Stephanou; Sarah Wetzig; Yueksel Cubuk; Johannes Gerharz; Ann-Kathrin Bittner; Mee Hoong See; Cornelia Liedtke; Hans-Christian Kolberg
Journal:  Breast Care (Basel)       Date:  2018-11-14       Impact factor: 2.860

9.  The Impact of Neoadjuvant Chemotherapy on Margin Re-excision in Breast-Conserving Surgery.

Authors:  Liam A Devane; Chwanrow K Baban; A O'Doherty; Cecily Quinn; Enda W McDermott; Ruth S Prichard
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

10.  Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma.

Authors:  Miriam L Hoven-Gondrie; Esther Bastiaannet; Vincent K Y Ho; Barbara L van Leeuwen; Gerrit-Jan Liefers; Harald J Hoekstra; Albert J H Suurmeijer
Journal:  Ann Surg Oncol       Date:  2016-03-08       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.